Last reviewed · How we verify
AV-GBM-1
AV-GBM-1 is an autologous dendritic cell vaccine designed to stimulate the patient's immune system to recognize and attack glioblastoma tumor cells.
AV-GBM-1 is an autologous dendritic cell vaccine designed to stimulate the patient's immune system to recognize and attack glioblastoma tumor cells. Used for Glioblastoma (newly diagnosed or recurrent).
At a glance
| Generic name | AV-GBM-1 |
|---|---|
| Sponsor | Aivita Biomedical, Inc. |
| Drug class | Autologous dendritic cell vaccine |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
The drug is manufactured by isolating dendritic cells from the patient, loading them with glioblastoma-associated antigens, and reinfusing them to prime T-cell responses against the tumor. This personalized immunotherapy approach aims to generate durable anti-tumor immunity in glioblastoma patients, typically used in combination with standard-of-care treatments.
Approved indications
- Glioblastoma (newly diagnosed or recurrent)
Common side effects
- Injection site reactions
- Fever
- Fatigue
- Headache
Key clinical trials
- AV-GBM-1 vs Control as Adjunctive Therapy Following Surgery and RT/TMZ in Newly Diagnosed GBM (PHASE3)
- Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas (PHASE2)
- Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |